Stony Brook Study on the Role of DNA Amplification in Cancer Chemoresistance Leverages KromaTiD dGH in-Site™ Technology

LONGMONT, Colo., Feb. 6, 2024 /PRNewswire/ — A Stony Brook University team of researchers led by Gábor Balázsi, PhD, has identified DNA amplification as a major cause of drug resistance in engineered mammalian cell lines and has identified a novel approach to overcome it in those cells…

Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks